We are analyzing https://link.springer.com/article/10.1007/s10072-020-04942-0.

Title:
Clinical features and management of coexisting anti-N-methyl-D-aspartate receptor encephalitis and myelin oligodendrocyte glycoprotein antibody–associated encephalomyelitis: a case report and review of the literature | Neurological Sciences
Description:
Background Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an autoimmune encephalitis caused by antibodies targeting the GluN1 subunit of NMDA receptors. Myelin oligodendrocyte glycoprotein (MOG) antibody disorders are now widely accepted as peculiar neuroimmunological diseases with specific clinical and pathological features. Some rare cases of overlapping anti-NMDA receptor encephalitis and MOG antibody–associated diseases have been reported, presenting complex clinical symptoms that make the disease more difficult to recognize. Method In accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, the terms “NMDAR” and “MOG,” “NMDAR” and “demyelination,” and “MOG” and “encephalitis” were searched in PubMed. Clinical cases with dual-positive anti-NMDA cerebrospinal fluid receptors and MOG serum antibodies during the disease course were included in this study. Results A total of 25 patients were analyzed in this study. The age at onset ranged from 3 to 54 years. The median number of relapses was 2.8. Administration of intravenous methylprednisolone and immunoglobulin was the most widely used treatment strategy (19/25 patients). Second-line treatments such as administration of mycophenolate mofetil, rituximab, interferon-β, azathioprine, cyclophosphamide, and temozolomide were also reported, followed by good outcomes. Conclusions The rates of coexisting anti-NMDA receptor encephalitis and MOG antibody–associated encephalomyelitis may be underestimated. Clinical symptoms such as seizures and cognitive decline accompanied by atypical central nervous system demyelination serve as warning signs of possible coexisting anti-NMDA receptor encephalitis and MOG antibody–associated encephalomyelitis. These patients could achieve good outcomes under proper immunotherapies.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

article, pubmed, google, scholar, encephalitis, cas, receptor, oligodendrocyte, glycoprotein, neurol, clinical, mog, central, myelin, antibodies, antibody, zhang, antinmethyldaspartate, antinmda, disease, demyelination, antibodyassociated, case, diseases, mult, scler, antinmdar, encephalomyelitis, study, httpsdoiorgs, dalmau, disord, data, jin, autoimmune, patients, antimyelin, demyelinating, relat, httpsdoiorgjmsard, privacy, cookies, content, analysis, information, research, neurological, features, coexisting, manuscript,

Topics {✒️}

anti-n-methyl-d-aspartate receptor encephalitis anti-methyl-d-aspartate receptor encephalitis n-methyl-d-aspartate receptor n-methyl-d-aspartate month download article/chapter anti-nmda-receptor encephalitis anti-nmda receptor encephalitis anti-nmdar encephalitis combined concomitant anti-nmdar encephalitis anti-nmda receptor antibodies persistent mog-igg positivity myelin oligodendrocyte glycoprotein anti-mog cns demyelination antibody disorders concomitant anti-mog anti-nmdar encephalitis inflammatory demyelinating diseases full article pdf single-center cohort study myelin/oligodendroglial glycoprotein nmda receptor antibodies titulaer mj anti-nmdar concurrent mog antibody disease overlapping demyelinating syndrome privacy choices/manage cookies anti-nmdar antibodies swedish research council neuro-inflammatory diseases relapsing mog-igg recurrent cns demyelination overlapping demyelinating syndromes cns inflammatory diseases myelin basic protein neurological update cerebral cortical encephalitis pediatric autoimmune encephalitis receptor encephalitis related subjects natural science foundation code availability autoimmune encephalitis caused optic neuritis anti-nmda article nan additional information publisher european economic area preferred reporting items cognitive decline accompanied differential ultrastructural localization

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Clinical features and management of coexisting anti-N-methyl-D-aspartate receptor encephalitis and myelin oligodendrocyte glycoprotein antibody–associated encephalomyelitis: a case report and review of the literature
         description:Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an autoimmune encephalitis caused by antibodies targeting the GluN1 subunit of NMDA receptors. Myelin oligodendrocyte glycoprotein (MOG) antibody disorders are now widely accepted as peculiar neuroimmunological diseases with specific clinical and pathological features. Some rare cases of overlapping anti-NMDA receptor encephalitis and MOG antibody–associated diseases have been reported, presenting complex clinical symptoms that make the disease more difficult to recognize. In accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, the terms “NMDAR” and “MOG,” “NMDAR” and “demyelination,” and “MOG” and “encephalitis” were searched in PubMed. Clinical cases with dual-positive anti-NMDA cerebrospinal fluid receptors and MOG serum antibodies during the disease course were included in this study. A total of 25 patients were analyzed in this study. The age at onset ranged from 3 to 54 years. The median number of relapses was 2.8. Administration of intravenous methylprednisolone and immunoglobulin was the most widely used treatment strategy (19/25 patients). Second-line treatments such as administration of mycophenolate mofetil, rituximab, interferon-β, azathioprine, cyclophosphamide, and temozolomide were also reported, followed by good outcomes. The rates of coexisting anti-NMDA receptor encephalitis and MOG antibody–associated encephalomyelitis may be underestimated. Clinical symptoms such as seizures and cognitive decline accompanied by atypical central nervous system demyelination serve as warning signs of possible coexisting anti-NMDA receptor encephalitis and MOG antibody–associated encephalomyelitis. These patients could achieve good outcomes under proper immunotherapies.
         datePublished:2021-01-07T00:00:00Z
         dateModified:2021-01-07T00:00:00Z
         pageStart:847
         pageEnd:855
         sameAs:https://doi.org/10.1007/s10072-020-04942-0
         keywords:
            Antibody
            Anti-NMDA receptor encephalitis
            MOG antibody–associated encephalomyelitis
            Symptoms
            Systematic review
            Neurology
            Neuroradiology
            Neurosurgery
            Psychiatry
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10072-020-04942-0/MediaObjects/10072_2020_4942_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10072-020-04942-0/MediaObjects/10072_2020_4942_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10072-020-04942-0/MediaObjects/10072_2020_4942_Fig3_HTML.png
         isPartOf:
            name:Neurological Sciences
            issn:
               1590-3478
               1590-1874
            volumeNumber:42
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Di Nan
               affiliation:
                     name:the First Hospital of Jilin University
                     address:
                        name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ying Zhang
               affiliation:
                     name:the First Hospital of Jilin University
                     address:
                        name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jinming Han
               affiliation:
                     name:the First Hospital of Jilin University
                     address:
                        name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
                     name:Karolinska Institutet
                     address:
                        name:Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tao Jin
               url:http://orcid.org/0000-0002-6084-3275
               affiliation:
                     name:the First Hospital of Jilin University
                     address:
                        name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Clinical features and management of coexisting anti-N-methyl-D-aspartate receptor encephalitis and myelin oligodendrocyte glycoprotein antibody–associated encephalomyelitis: a case report and review of the literature
      description:Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an autoimmune encephalitis caused by antibodies targeting the GluN1 subunit of NMDA receptors. Myelin oligodendrocyte glycoprotein (MOG) antibody disorders are now widely accepted as peculiar neuroimmunological diseases with specific clinical and pathological features. Some rare cases of overlapping anti-NMDA receptor encephalitis and MOG antibody–associated diseases have been reported, presenting complex clinical symptoms that make the disease more difficult to recognize. In accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, the terms “NMDAR” and “MOG,” “NMDAR” and “demyelination,” and “MOG” and “encephalitis” were searched in PubMed. Clinical cases with dual-positive anti-NMDA cerebrospinal fluid receptors and MOG serum antibodies during the disease course were included in this study. A total of 25 patients were analyzed in this study. The age at onset ranged from 3 to 54 years. The median number of relapses was 2.8. Administration of intravenous methylprednisolone and immunoglobulin was the most widely used treatment strategy (19/25 patients). Second-line treatments such as administration of mycophenolate mofetil, rituximab, interferon-β, azathioprine, cyclophosphamide, and temozolomide were also reported, followed by good outcomes. The rates of coexisting anti-NMDA receptor encephalitis and MOG antibody–associated encephalomyelitis may be underestimated. Clinical symptoms such as seizures and cognitive decline accompanied by atypical central nervous system demyelination serve as warning signs of possible coexisting anti-NMDA receptor encephalitis and MOG antibody–associated encephalomyelitis. These patients could achieve good outcomes under proper immunotherapies.
      datePublished:2021-01-07T00:00:00Z
      dateModified:2021-01-07T00:00:00Z
      pageStart:847
      pageEnd:855
      sameAs:https://doi.org/10.1007/s10072-020-04942-0
      keywords:
         Antibody
         Anti-NMDA receptor encephalitis
         MOG antibody–associated encephalomyelitis
         Symptoms
         Systematic review
         Neurology
         Neuroradiology
         Neurosurgery
         Psychiatry
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10072-020-04942-0/MediaObjects/10072_2020_4942_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10072-020-04942-0/MediaObjects/10072_2020_4942_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10072-020-04942-0/MediaObjects/10072_2020_4942_Fig3_HTML.png
      isPartOf:
         name:Neurological Sciences
         issn:
            1590-3478
            1590-1874
         volumeNumber:42
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Di Nan
            affiliation:
                  name:the First Hospital of Jilin University
                  address:
                     name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ying Zhang
            affiliation:
                  name:the First Hospital of Jilin University
                  address:
                     name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jinming Han
            affiliation:
                  name:the First Hospital of Jilin University
                  address:
                     name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
                  name:Karolinska Institutet
                  address:
                     name:Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tao Jin
            url:http://orcid.org/0000-0002-6084-3275
            affiliation:
                  name:the First Hospital of Jilin University
                  address:
                     name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Neurological Sciences
      issn:
         1590-3478
         1590-1874
      volumeNumber:42
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:the First Hospital of Jilin University
      address:
         name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
         type:PostalAddress
      name:the First Hospital of Jilin University
      address:
         name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
         type:PostalAddress
      name:the First Hospital of Jilin University
      address:
         name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
         type:PostalAddress
      name:Karolinska Institutet
      address:
         name:Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden
         type:PostalAddress
      name:the First Hospital of Jilin University
      address:
         name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Di Nan
      affiliation:
            name:the First Hospital of Jilin University
            address:
               name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
      name:Ying Zhang
      affiliation:
            name:the First Hospital of Jilin University
            address:
               name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
      name:Jinming Han
      affiliation:
            name:the First Hospital of Jilin University
            address:
               name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
            name:Karolinska Institutet
            address:
               name:Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden
               type:PostalAddress
            type:Organization
      name:Tao Jin
      url:http://orcid.org/0000-0002-6084-3275
      affiliation:
            name:the First Hospital of Jilin University
            address:
               name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
      name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
      name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
      name:Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden
      name:Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(208)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.79s.

LINK . SPRINGER . COM {}